摘要
目的:探讨柳氮磺吡啶联合复方谷氨酰胺治疗溃疡性结肠炎(UC)的临床疗效,以及对患者血清降钙素原(PCT)、C反应蛋白(CRP)的影响。方法:将2020年6月至2022年6月我院收治的90例UC患者随机分为观察组和对照组,每组45例,对照组口服柳氮磺吡啶治疗,观察组在对照组基础上予以复方谷氨酰胺口服。比较2组临床疗效,治疗前后患者血清PCT、CRP水平,以及不良反应。结果:观察组治疗总有效率明显高于对照组,P<0.05。治疗后,2组PCT、CRP水平均较治疗前降低,其中观察组更低,P<0.05。2组不良反应发生率比较差异无统计学意义,P>0.05,且均无严重不良反应发生。结论:柳氮磺吡啶联合复方谷氨酰胺治疗UC临床疗效显著,可显著降低血清PCT、CRP水平,且安全性高,值得临床推广应用。
Objective To investigate the clinical effect of salazosulfapyridine combined with compound glutamine in the treatment ulcerative colitis(UC),as well as the influence on patients'serum procalcitonin(PCT)and C-reactive protein(CRP).Methods Randomly divided 90UC patients treated in author's hospital(2020-06-2022-06)into control group(45cases,oral administered salazosulfapyridine)and obsevation group(45cases,based on control group,added with compound glutamine);then,compared both groups'clinical effect,the levels of serum PCT and CRP before and after treatment,as well as adverse reactions.Results In total effective rate observation group was significantly higher than control group(P<0.05);after treatment the levels of PCT and CRP in both groups were declined,but in observation group,more lower(P<0.05);in the incidence of adverse reactions there was no statistical difference between the two groups(P>0.05),and,no severe adverse reactions were all found in both groups.Conclusion The combination of both drugs in the treatment of UC has significant effect,clinically,and can greatly reduce serum levels of PCT and CRP,also,its safety is high,thus worth to be popularized to use clinically.
作者
李俐
李丹
秦瑶
海星
李想
LI Li;LI Dan;QIN Yao;HAI Xing;LI Xiang(Zhengzhou City's Third People's Hospital,Zhengzhou,Henan 450000)
出处
《中国肛肠病杂志》
2023年第2期23-25,共3页
Chinese Journal of Coloproctology
关键词
溃疡性结肠炎
柳氮磺吡啶
复方谷氨酰胺
降钙素原
C反应蛋白
疗效
Ulcerative colitis
Salazosulfapyridine
Compound glutamine
Procalcitonin
C-reactive protein
Curative effect
